John Heymach, MD, PhD
Enriched profileChair, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine; Professor of Thoracic/Head and Neck Medical Oncology & Cancer Biology (joint appointment) · The University of Texas MD Anderson Cancer Center
John Heymach is Chair, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine; Professor of Thoracic/Head and Neck Medical Oncology & Cancer Biology (joint appointment) at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 2,459 publications with 69,203 citations (h-index 131); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists John Heymach as a Highly Cited Researcher (Clinical Medicine, 2022-2024).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
John Heymach, M.D., is Chair, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 2,459 publications with 69,203 citations (h-index 131), centered on Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 37 companies, 10 NIH-funded awards (2011–2026).
- Most recent indexed publication: 2026 · Nature communications
- Top research focus: Lung Cancer Treatments and Mutations
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 37 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 98 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 555.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 27 Aug 2026
37 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20254 payments$21,957openpaymentsdata.cms.gov ↗
- BioNTech SEProgram year20258 payments$21,486openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20257 payments$19,705openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
83.9%Kinase inhibitor83.9%Tagrisso100%Part D<11 patientsNervous system
16.1%Opioid Agonist16.1%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
10 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:
- Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer
University of Tx Md Anderson Can Ctr
FY2026$679,129R01CA287279 - Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer
University of Tx Md Anderson Can Ctr
FY2025$695,004R01CA287279 - Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
University of Tx Md Anderson Can Ctr
FY2025$605,520U01CA256780
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Deciphering small sequence differences in T cell receptor-antigen pairing.
Nature communications
Article2026 - FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer.
Cancer immunology research
Article2026 - BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.
Molecular cancer therapeutics
Article2026
Most-cited works
by citation count (OpenAlex)- 01Lung Cancer2,392 citations2008
- 02
- 03
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Google Scholar
scholar.google.com/citations
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholar.google.com ↗ - ResearchGate
researchgate.net/profile/John-Heymach
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/onclive_john-heymach-md-phd-of-md-anderson-cancer-activity-7333628143028576258-r5ok
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Other
videopodcast.researchtopractice.com/lung-cancer-john-v-heymach-md-phd
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →videopodcast.researchtopractice.com ↗ - Other
lung-cancer-update.captivate.fm/episode/5684-oncologytodayheralterednsclc25
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lung-cancer-update.captivate.fm ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Medical Oncology Fellowship
Dana-Farber/Partners CancerCare Program (Dana-Farber/Mass General Brigham), Boston
2003verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- Leader
Lung Cancer Moon Shot program, MD Anderson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Co-Director/Project Leader
Lung Cancer SPORE (Specialized Program of Research Excellence)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Chair
National Cancer Institute Molecular Cancer Therapeutics-1 (MCT-1) study section
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →public.era.nih.gov ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine202220232024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- LCRF-Boehringer Ingelheim Team Science Award (lead investigator)
Lung Cancer Research Foundation, 2026 - understanding/treating HER2-mutant lung cancers
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lungcancerresearchfoundation.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lungevity.org ↗
- David Bruton Jr. Endowed Chair in Cancer Research
MD Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- Faculty Member
UT MD Anderson UTHealth Houston Graduate School of Biomedical Sciences
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gsbs.uth.edu ↗ - Member
Scientific Advisory Board, ModeX Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →modextherapeutics.com ↗ - Member
Scientific Advisory Board, Lung Cancer Research Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lungcancerresearchfoundation.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lung-cancer-update.captivate.fm ↗
- Featured expert speaker
Houston Oncology Summit (BiotechTV) - TKIs, KRAS, bispecifics discussion, Sept 26 2024
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biotechtv.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center